- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Vimida
Disease: Post-COVID-19
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- General population
- Adolescents (12-17 years)
- Non-hospital health centre
- Telemedicine
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Hydroxy gas
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Temelimab
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Outpatient clinic
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- Fragile population
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation